|
ES2649817T3
(es)
|
2002-04-05 |
2018-01-15 |
Roche Innovation Center Copenhagen A/S |
Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
|
|
CA2515623A1
(en)
|
2003-02-10 |
2004-08-19 |
Santaris Pharma A/S |
Oligomeric compounds for the modulation of survivin expression
|
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
|
AU2004221760B2
(en)
|
2003-03-21 |
2010-03-18 |
Roche Innovation Center Copenhagen A/S |
Short interfering RNA (siRNA) analogues
|
|
ES2344566T3
(es)
|
2003-12-23 |
2010-08-31 |
Santaris Pharma A/S |
Compuestos oligomericos para la modulacion de bcl-2.
|
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
|
EP1824975B9
(de)
|
2004-11-09 |
2011-04-20 |
Santaris Pharma A/S |
Lna-oligonukleotide und krebsbehandlung
|
|
BRPI0515726A8
(pt)
|
2004-11-09 |
2017-09-12 |
Santaris Pharma As |
Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a
|
|
US20090324587A1
(en)
|
2005-12-01 |
2009-12-31 |
Neal Clifford Goodwin |
Cancer Therapies and Pharmaceutical Compositions Used Therein
|
|
ES2556128T3
(es)
|
2006-03-23 |
2016-01-13 |
Roche Innovation Center Copenhagen A/S |
ARN interfiriente pequeño internamente segmentado
|
|
CA3042781C
(en)
|
2006-04-03 |
2021-10-19 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
EA201100811A1
(ru)
|
2006-04-03 |
2012-06-29 |
Сантарис Фарма А/С |
Фармацевтическая композиция
|
|
US8470791B2
(en)
|
2007-03-22 |
2013-06-25 |
Santaris Pharma A/S |
RNA antagonist compounds for the inhibition of Apo-B100 expression
|
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
ES2798758T3
(es)
|
2007-06-06 |
2020-12-14 |
Sarepta Therapeutics Inc |
Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
|
|
EP2183360B1
(de)
|
2007-08-30 |
2017-01-11 |
Hadasit Medical Research Services&Development Company Ltd. |
Nukleinsäuresequenzen mit nf-(kappa)b-bindungsstelle innerhalb eines o(6)-methylguanin-dna-methyltransferase (mgmt)-promoter-bereichs und ihre verwendung zur behandlung von krebs und immunbedingten erkrankungen
|
|
DK2205737T3
(da)
|
2007-10-04 |
2013-05-21 |
Santaris Pharma As |
Mikromirer
|
|
EP2212437A4
(de)
|
2007-11-07 |
2011-09-28 |
Univ British Columbia |
Mikrofluidische vorrichtung und verfahren zu ihrer anwendung
|
|
EP2268811A1
(de)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmazeutische zusammensetzungen zur behandlung von krankheiten in verbindung mit microrna
|
|
US8492357B2
(en)
|
2008-08-01 |
2013-07-23 |
Santaris Pharma A/S |
Micro-RNA mediated modulation of colony stimulating factors
|
|
US9034837B2
(en)
|
2009-04-24 |
2015-05-19 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
|
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
|
GB201012418D0
(en)
|
2010-07-23 |
2010-09-08 |
Santaris Pharma As |
Process
|
|
JP6106085B2
(ja)
|
2010-08-24 |
2017-03-29 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
内部非核酸スペーサーを含む一本鎖RNAi剤
|
|
CN104884637A
(zh)
|
2012-11-05 |
2015-09-02 |
普隆奈治疗公司 |
利用生物标志物通过bcl2表达的调节治疗癌症的方法
|
|
EP2943570B1
(de)
|
2013-01-14 |
2018-01-03 |
Pierfrancesco Tassone |
Inhibitoren von mirnas 221 und 222 zur antitumorwirkung bei multiplem myelom
|
|
MX367083B
(es)
|
2013-06-27 |
2019-08-05 |
Roche Innovation Ct Copenhagen As |
Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
|
|
WO2015075166A1
(en)
|
2013-11-22 |
2015-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of a bacterial infection
|
|
US9765332B2
(en)
|
2014-01-29 |
2017-09-19 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
US10533172B2
(en)
|
2014-09-18 |
2020-01-14 |
The University Of British Columbia |
Allele-specific therapy for huntington disease haplotypes
|
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
|
KR20180043819A
(ko)
*
|
2015-08-24 |
2018-04-30 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Lna-g 방법
|
|
CN108603230A
(zh)
|
2015-10-09 |
2018-09-28 |
南安普敦大学 |
基因表达的调节与蛋白质表达失调的筛选
|
|
CN116059236A
(zh)
|
2015-12-14 |
2023-05-05 |
冷泉港实验室 |
用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
US20220354888A1
(en)
|
2016-08-03 |
2022-11-10 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
|
KR20260009385A
(ko)
|
2017-08-25 |
2026-01-19 |
스톡 테라퓨틱스, 인크. |
병태 및 질환 치료용 안티센스 올리고머
|
|
EP3697904A1
(de)
|
2017-10-17 |
2020-08-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationsbehandlung für zystische fibrose
|
|
JP2021523227A
(ja)
|
2018-05-04 |
2021-09-02 |
ストーク セラピューティクス,インク. |
コレステリルエステル蓄積症の処置のための方法及び組成物
|
|
KR20210134003A
(ko)
|
2019-02-27 |
2021-11-08 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 안티센스 올리고머
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
IT201900017234A1
(it)
|
2019-09-25 |
2021-03-25 |
Int Centre For Genetic Engineering And Biotechnology |
Anti-miRNA per il trattamento del leiomioma
|
|
WO2021074657A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment for cystic fibrosis
|
|
EP4047005A4
(de)
*
|
2019-10-18 |
2024-03-06 |
Daiichi Sankyo Company, Limited |
Verfahren zur herstellung von bicyclischem phosphoramidit
|
|
EP4059944A4
(de)
*
|
2019-11-13 |
2024-04-10 |
Nippon Shinyaku Co., Ltd. |
Verfahren zur herstellung einer oligonukleidsäureverbindung
|
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
US12338437B2
(en)
|
2020-05-11 |
2025-06-24 |
Stoke Therapeutics, Inc. |
OPA1 antisense oligomers for treatment of conditions and diseases
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
KR20230118076A
(ko)
|
2020-12-11 |
2023-08-10 |
야마사 쇼유 가부시키가이샤 |
시토신형 가교형 뉴클레오시드 아미다이트 결정 및 그 제조 방법
|
|
IL304956A
(en)
|
2021-02-12 |
2023-10-01 |
Merand Pharmaceuticals Inc |
Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
|
|
MX2023011101A
(es)
|
2021-03-26 |
2024-01-10 |
Neumirna Therapeutics Aps |
Inhibidores de microrna-27b.
|
|
KR20230170690A
(ko)
|
2021-03-26 |
2023-12-19 |
뉴미르나 테라퓨틱스 에이피에스 |
MicroRNA-134 억제제들
|
|
JP2024522272A
(ja)
|
2021-06-04 |
2024-06-13 |
ニューミルナ セラピューティクス エーピーエス |
アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
|
|
AU2022329834A1
(en)
|
2021-08-17 |
2024-03-07 |
Korea Advanced Institute Of Science And Technology |
Antisense oligonucleotide targeting cav3.1 gene and uses thereof
|
|
EP4388096A1
(de)
|
2021-08-19 |
2024-06-26 |
Neumirna Therapeutics ApS |
Antisense oligonukleotide gegen adenosinkinase
|
|
JP7772362B2
(ja)
*
|
2021-12-21 |
2025-11-18 |
シンクレスト株式会社 |
人工核酸モノマーの製造方法
|
|
WO2023152369A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
|
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
EP4332239A1
(de)
|
2022-08-30 |
2024-03-06 |
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. |
Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
|
|
WO2024146935A1
(en)
|
2023-01-06 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
EP4450626A1
(de)
|
2023-04-21 |
2024-10-23 |
IFOM - Istituto Fondazione di Oncologia Molecolare ETS |
Frnip2-inhibitoren zur behandlung von ataxie telangiectasia
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
EP4512899A1
(de)
|
2023-08-23 |
2025-02-26 |
Lipigon Pharmaceuticals AB |
Angptl4-aso-zusammensetzungen zur behandlung von atherosklerose bei menschen
|
|
CN117233282B
(zh)
*
|
2023-09-14 |
2024-12-20 |
上海奥锐特生物科技有限公司 |
2-氰乙基-n,n,n’,n’-四异丙基亚磷酰二胺的检测方法
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
WO2026061986A1
(en)
|
2024-09-17 |
2026-03-26 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
|
|
WO2026068729A1
(en)
|
2024-09-26 |
2026-04-02 |
Neumirna Therapeutics Aps |
Antimir-27b for treatment of parkinson's disease
|
|
EP4763209A1
(de)
|
2024-12-17 |
2026-06-24 |
Institut National de la Santé et de la Recherche Médicale |
Verwendung von (alpha)s-semar-agonisten zur vorbeugung oder behandlung von glioblastom
|